[Amiodarone-induced thyrotoxicosis: case report and review of the literature]. 2003

Michele Bianconcini, and Alfredo L Giannini
U.O. di Medicina Interna e Malattie Cardiache Azienda Ospedaliera Universitaria Via Gramsci, 14 43100 Parma. mbianconcini@ao.pr.it

We report a case of amiodarone-induced thyrotoxicosis, and a broad review of the literature. Amiodarone is a drug widely used in cardiovascular medicine. Since it is iodine-rich, it may cause changes in thyroid function tests in some patients under chronic treatment. In 14-18% of amiodarone-treated patients, there is overt thyroid dysfunction (hypothyroidism or thyrotoxicosis). We here describe thyrotoxicosis, which can be distinguished in two subtypes differing in pathogenesis and treatment. Type I is primarily related to an excess of iodine-induced thyroid hormone synthesis in an abnormal thyroid gland, and the main medical treatment consists of the simultaneous administration of thionamides and potassium perchlorate. Type II is due to amiodarone-related destructive thyroiditis and glucocorticoids are therapy of choice. Mixed forms frequently exist. Due to the low thyroidal iodine uptake, radioiodine therapy is usually not efficacious. Surgical treatment can be performed in cases resistant to medical therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008713 Methimazole A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Methymazol,Thiamazole,1-Methyl-2-mercaptoimidazole,Favistan,Mercasolyl,Mercazol,Mercazole,Mercazolyl,Merkazolil,Methizol,Methylmercaptoimidazole,Metisol,Metizol,Strumazol,Tapazole,Thiamazol Henning,Thiamazol Hexal,Thimazol,Thyrozol,Tiamazol,Tirodril,1 Methyl 2 mercaptoimidazole,Henning, Thiamazol,Hexal, Thiamazol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000638 Amiodarone An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. Amiobeta,Amiodarex,Amiodarona,Amiodarone Hydrochloride,Amiohexal,Aratac,Braxan,Corbionax,Cordarex,Cordarone,Kordaron,L-3428,Ortacrone,Rytmarone,SKF 33134-A,Tachydaron,Trangorex,Hydrochloride, Amiodarone,L 3428,L3428,SKF 33134 A,SKF 33134A
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D013956 Antithyroid Agents Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones. Antithyroid Agent,Antithyroid Drug,Goitrogen,Goitrogens,Thyroid Antagonists,Antithyroid Drugs,Antithyroid Effect,Antithyroid Effects,Agent, Antithyroid,Agents, Antithyroid,Antagonists, Thyroid,Drug, Antithyroid,Drugs, Antithyroid,Effect, Antithyroid,Effects, Antithyroid
D013971 Thyrotoxicosis A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING. Thyrotoxicoses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017180 Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). Idiopathic Ventricular Tachycardia,Nonsustained Ventricular Tachycardia,Paroxysmal Supraventricular Tachycardia,Ventricular Tachyarrhythmias,Ventricular Tachycardia,Idiopathic Ventricular Tachycardias,Nonsustained Ventricular Tachycardias,Paroxysmal Supraventricular Tachycardias,Supraventricular Tachycardia, Paroxysmal,Tachyarrhythmia, Ventricular,Tachycardia, Idiopathic Ventricular,Tachycardia, Nonsustained Ventricular,Tachycardia, Paroxysmal Supraventricular,Ventricular Tachyarrhythmia,Ventricular Tachycardia, Idiopathic,Ventricular Tachycardia, Nonsustained,Ventricular Tachycardias

Related Publications

Michele Bianconcini, and Alfredo L Giannini
October 2000, The American journal of the medical sciences,
Michele Bianconcini, and Alfredo L Giannini
November 2021, Arquivos brasileiros de cardiologia,
Michele Bianconcini, and Alfredo L Giannini
November 2009, The Journal of laryngology and otology,
Michele Bianconcini, and Alfredo L Giannini
May 1980, Postgraduate medical journal,
Michele Bianconcini, and Alfredo L Giannini
February 2019, Annales d'endocrinologie,
Michele Bianconcini, and Alfredo L Giannini
January 2013, Boletin de la Asociacion Medica de Puerto Rico,
Michele Bianconcini, and Alfredo L Giannini
February 2001, Anaesthesia and intensive care,
Michele Bianconcini, and Alfredo L Giannini
November 2007, Anales de medicina interna (Madrid, Spain : 1984),
Michele Bianconcini, and Alfredo L Giannini
April 2015, QJM : monthly journal of the Association of Physicians,
Copied contents to your clipboard!